Patients' Quality of Life Improves After Surgical Intervention of Stage III Medication-related Osteonecrosis of the Jaw

Overview

Journal Oral Maxillofac Surg

Specialties Dentistry
General Surgery

Date 2020 Nov 23

PMID 33226530

Citations 7

Authors

Stefan Moll

Steffen Mueller

Johannes K Meier

Torsten E Reichert

Tobias Ettl

Christoph Klingelhoffer

Affiliations

Soon will be listed here.

Abstract

Purpose: The treatment of advanced stages of medication-related osteonecrosis of the jaw (MRONJ) remains challenging. In order to improve decision making concerning the therapy, we examined the change of patients' quality of life (QoL) after surgical treatment of MRONJ stage III.

Method: The primary outcome variable was patients' QoL. It was preoperative (T0), 6 weeks postoperative (T1) and 6 months postoperative (T2) assessed by the European Organisation for Research and Treatment of Cancer QoL-H&N35 (EORTC QoL-H&N35) and the Oral Health Impact Factor-G14 (OHIP-G14) questionnaire in a prospective cohort study. Other variables included location, age, sex, risk factors, and recurrence. Descriptive statistics and general multivariate regression models were calculated.

Results: Forty-three patients with stage III MRONJ underwent surgery. OHIP-G14 scores decreased (improvement) statistically significant (p = .001) by 52.02% (T0-T1) and 56.45% (T1-T2). EORTC QoL-H&N35 showed statistical improvement for "swallowing" (p = .007), "opening mouth" (p = .045), "painkiller" (.005), "weight loss" (.004), "pain" (p = .001), "trouble with social eating" (p = .001), "trouble with social contact" (p = .001), and "teeth" (p = .001). Patients who developed a recurrence did not show any significant higher (worse) scores in OHIP G14 or EORTC QoL-H&N35 scores compared with patients without recurrence. Twenty-nine out of 36 patients showed full mucosal healing (T2). For patients with no full mucosal healing, a downgrade to stage I was achieved.

Conclusion: In terms of QoL patients with stage III MRONJ do benefit from surgical treatment. The incident of a recurrence seems to have no significant impact on patients QoL.

Citing Articles

The Role of Cone Beam Computed Tomography (CBCT) in the Diagnosis and Clinical Management of Medication-Related Osteonecrosis of the Jaw (MRONJ).

Ko Y, Yang W, Leung Y Diagnostics (Basel). 2024; 14(16).

PMID: 39202187 PMC: 11353876. DOI: 10.3390/diagnostics14161700.

Improvement of Quality of Life after Surgical Treatment of Patients with MRONJ: A Prospective Analysis Using the SF-12 and OHIP-14 Questionnaires.

Hoene G, von Hahn N, Sievers D, Schuffelen L, Wolfer S, Goldstein K Int J Dent. 2024; 2024:4435791.

PMID: 38715871 PMC: 11074825. DOI: 10.1155/2024/4435791.

Calabria E, Antonelli A, Barone S, Adamo D, Salviati M, Cerra M Dent J (Basel). 2023; 11(6).

PMID: 37366670 PMC: 10297522. DOI: 10.3390/dj11060147.

Associated systemic diseases and etiologies of medication-related osteonecrosis of the jaw: a retrospective study of 265 surgical cases.

Chang H, Kim M, Ahn K Maxillofac Plast Reconstr Surg. 2023; 45(1):12.

PMID: 36853370 PMC: 9975129. DOI: 10.1186/s40902-023-00377-7.

Comparing the Influence of Surgical and Conservative Therapy on Quality of Life in Patients with Early-Stage Medication-Related Osteonecrosis of the Jaw-A Prospective Longitudinal Study.

Ruckschloss T, Smielowski M, Moratin J, Schnug G, Appel M, Muench P Medicina (Kaunas). 2023; 59(2).

PMID: 36837478 PMC: 9966476. DOI: 10.3390/medicina59020277.

References

Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B . American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938-56. DOI: 10.1016/j.joms.2014.04.031. View

Otto S, Troltzsch M, Jambrovic V, Panya S, Probst F, Ristow O . Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?. J Craniomaxillofac Surg. 2015; 43(6):847-54. DOI: 10.1016/j.jcms.2015.03.039. View

Khan A, Morrison A, Hanley D, Felsenberg D, McCauley L, ORyan F . Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2014; 30(1):3-23. DOI: 10.1002/jbmr.2405. View

Otto S, Ristow O, Pache C, Troeltzsch M, Fliefel R, Ehrenfeld M . Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: A prospective cohort study. J Craniomaxillofac Surg. 2016; 44(8):1073-80. DOI: 10.1016/j.jcms.2016.05.018. View

Sadiq Z, Sammut S, Lopes V . Non-complex reconstructive techniques in the management of BRONJ: a case series of patient-related outcomes. Oral Maxillofac Surg. 2014; 18(2):223-7. DOI: 10.1007/s10006-013-0440-3. View

Ristow O, Ruckschloss T, Bodem J, Berger M, Bodem E, Kargus S . Double-layer closure techniques after bone surgery of medication-related osteonecrosis of the jaw - A single center cohort study. J Craniomaxillofac Surg. 2018; 46(5):815-824. DOI: 10.1016/j.jcms.2018.03.005. View

Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis C . Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009; 27(32):5356-62. DOI: 10.1200/JCO.2009.21.9584. View

Marx R . Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003; 61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1. View

Aaronson N, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez N . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85(5):365-76. DOI: 10.1093/jnci/85.5.365. View

10.

Miksad R, Lai K, Dodson T, Woo S, Treister N, Akinyemi O . Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist. 2011; 16(1):121-32. PMC: 3228058. DOI: 10.1634/theoncologist.2010-0183. View

11.

Bjordal K, de Graeff A, Fayers P, Hammerlid E, van Pottelsberghe C, Curran D . A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer. 2000; 36(14):1796-807. DOI: 10.1016/s0959-8049(00)00186-6. View

12.

Kyrgidis A, Triaridis S, Kontos K, Patrikidou A, Andreadis C, Constantinidis J . Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires. Anticancer Res. 2012; 32(8):3527-34. View

13.

Saad F, Brown J, Van Poznak C, Ibrahim T, Stemmer S, Stopeck A . Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2011; 23(5):1341-1347. DOI: 10.1093/annonc/mdr435. View

14.

SILVERSTEIN P . Smoking and wound healing. Am J Med. 1992; 93(1A):22S-24S. DOI: 10.1016/0002-9343(92)90623-j. View

15.

Oteri G, De Ponte F, Runci M, Peditto M, Marciano A, Cicciu M . Oral-Health-Related Quality of Life After Surgical Treatment of Osteonecrosis of the Jaws. J Craniofac Surg. 2017; 29(2):403-408. DOI: 10.1097/SCS.0000000000004087. View

16.

Jensen K, Jensen A, Grau C . A cross sectional quality of life study of 116 recurrence free head and neck cancer patients. The first use of EORTC H&N35 in Danish. Acta Oncol. 2006; 45(1):28-37. DOI: 10.1080/02841860500417536. View

17.

Singer S, Araujo C, Arraras J, Baumann I, Boehm A, Herlofson B . Measuring quality of life in patients with head and neck cancer: Update of the EORTC QLQ-H&N Module, Phase III. Head Neck. 2014; 37(9):1358-67. DOI: 10.1002/hed.23762. View

18.

Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiodt M . Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018; 69:177-187. DOI: 10.1016/j.ctrv.2018.06.007. View

19.

Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E . Medication-related osteonecrosis of the jaw: Surgical or non-surgical treatment?. Oral Dis. 2018; 24(1-2):238-242. DOI: 10.1111/odi.12764. View

20.

Vanpoecke J, Verstraete L, Smeets M, Ferri J, Nicot R, Politis C . Medication-related osteonecrosis of the jaw (MRONJ) stage III: Conservative and conservative surgical approaches versus an aggressive surgical intervention: A systematic review. J Craniomaxillofac Surg. 2020; 48(4):435-443. DOI: 10.1016/j.jcms.2020.02.017. View